Volume 21, Issue 3 (6-2018)
J Arak Uni Med Sci 2018, 21(3): 65-74 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shahsavandi S, Ebrahimi M M, Samiee M R. Promotion the Immunogenicity of Chitosan Nanoparticle-Based Influenza Vaccine Using Hemokinin-1. J Arak Uni Med Sci 2018; 21 (3) :65-74
URL: http://jams.arakmu.ac.ir/article-1-5644-en.html
URL: http://jams.arakmu.ac.ir/article-1-5644-en.html
1- Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran. , s.shahsavandi@rusti.ac.ir
2- Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
2- Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
Abstract: (2471 Views)
Background and Aim: The inactivated vaccines are formulated with adjuvant to direct the host immune responses and also increase stability of the antigen. In recent years, the development of biological adjuvants and the evaluation of their ability in elicitation of immune responses against influenza virus have been considered. Hemokinin-1 (HK-1) activates T and B cells for differentiation into plasma cells, and antibody production. In this study, the effect of HK-1 for inducing humoral immune response against influenza chitosan based-nano vaccine was investigated.
Materials and Methods: Chitosan nanoparticle containing inactivated influenza antigen and chitosan nanoparticle containing the inactivated antigen formulated with HK-1 were prepared. Immune response following influenza nanoparticles vaccinations with and without the adjuvant was assessed in SPF chickens after prime and boost immunizations. Specific antibody levels against influenza were evaluated in serum samples of treatment and control groups by serological tests.
Findings: The chickens immunized with the HK-1 adjuvanted nano vaccine produced higher specific antibody titers that were sustained until the end of experiment comparable either with inactivated antigen alone or the H9N2 nanoparticles without HK-1 adjuvant. Administration of boosting had no effect on the enhancing of antibody titer.
Conclusion: The data show that the chitosan nanoparticles provide better absorption conditions and more stability and release of the influenza antigen in the presence of HK-1 biological adjuvant.
Materials and Methods: Chitosan nanoparticle containing inactivated influenza antigen and chitosan nanoparticle containing the inactivated antigen formulated with HK-1 were prepared. Immune response following influenza nanoparticles vaccinations with and without the adjuvant was assessed in SPF chickens after prime and boost immunizations. Specific antibody levels against influenza were evaluated in serum samples of treatment and control groups by serological tests.
Findings: The chickens immunized with the HK-1 adjuvanted nano vaccine produced higher specific antibody titers that were sustained until the end of experiment comparable either with inactivated antigen alone or the H9N2 nanoparticles without HK-1 adjuvant. Administration of boosting had no effect on the enhancing of antibody titer.
Conclusion: The data show that the chitosan nanoparticles provide better absorption conditions and more stability and release of the influenza antigen in the presence of HK-1 biological adjuvant.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2018/02/24 | Accepted: 2018/05/9
Received: 2018/02/24 | Accepted: 2018/05/9
References
1. Lee CW, Suarez D. Avian influenza virus: prospects for prevention and control by vaccination. Animal Health research Review. 2005; 6: 1-15.
2. van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses. 2012; 4(9):1438-76.
3. Johnson PA, Conway MA, Daly J, Nicolson C, Robertson J, Mills KH. Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. Journal of General Virology. 2000; 81(7):1737-45.
4. Lupfer C, Thomas PG, Kanneganti T-D. Nucleotide oligomerization and binding domain 2-dependent dendritic cell activation is necessary for innate immunity and optimal CD8+ T cell responses to influenza A virus infection. Journal of Virology. 2014; 88 (16):8946-55.
5. Roth J. Adjuvants in veterinary vaccines: Modes of action to enhance the immune response. Potential adverse effects, Journal of Veterinary International Medicine, 2003; 17:273-281.
6. Lima KM, dos Santos SA, Rodrigues Jr JM, Silva CL. Vaccine adjuvant: it makes the difference. Vaccine. 2004; 22(19):2374-9.
7. Fox CB, Kramer RM, Barnes L, Dowling QM, Vedvick TS. Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines. 2013; 1:7-20.
8. Tovey MG, Lallemand C. Adjuvant activity of cytokines. Methods in Molecular Biology. 2010; 626:287-309.
9. Song H, Yin W, Zeng Q, Jia H, Lin L, Liu X, et al. Hemokinins modulate endothelium function and promote angiogenesis through neurokinin-1 receptor. The International Journal of Biochemistry & Cell Biology. 2012; 44:1410-21.
10. Khalili I, Ghadimipour R, Sadigh Eteghad S, Fathi Najafi M, Ebrahimi MM, Godsian N, Sefidi Heris Y, Khalili MT. Evaluation of immune response against inactivated avian influenza (H9N2) vaccine, by using chitosan nanoparticles. Jundishapur Journal of Microbiology. 2015; 8(12): e27035.
11. Sadeghi K, Shahsavandi S, Ebrahimi MM, Mehravani H, Fazel H. Hemokinin-1 molecular adjuvant: an approach to enhance the efficacy of influenza vaccine. Arak Medical University Journal (AMUJ). 2014; 17: 62-69.
12. Shahsavandi S, Ebrahimi MM; Sadeghi K; Mahravani H. Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses. Virologica Sinica. 2015; 30: 1-8.
13. Zhang Y, Paige CJ. T-cell developmental blockage by tachykinin antagonists and the role of hemokinin 1 in T lymphopoiesis. Blood. 2003; 102: 2165-72.
14. Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines. 2012; 11:595-607.
15. Zhao L, Seth A. Nanoparticle Vaccines. Vaccine. 2014; 32:327-337.
16. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Advanced Drug Delivery Reviews. 2010; 62: 28–41.
17. Zhang J, Xia W, Liu P, Cheng Q, Tahirou T, Gu W, et al. Chitosan modification and pharmaceutical/biomedical Applications. Marine Drugs. 2010; 8: 1962-1987.
18. Ghendon Y, Markushin S, Krivtsov G, Akopova I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Archives of Virology. 2008; 153:831–837.
19. Dehghan A., Shahsavandi S., Jabalameli L. Improvement efficacy of H9N2 influenza nanovaccine in combination with hemokinin-1 molecular adjuvant. Avicenna Journal of Medical Biotechnology. 2018; 10 (in press).
20. Shahsavandi S, Salmanian AH, Ghorashi SA, Masoudi S, Ebrahimi MM. Evolutionary characterization of hemagglutinin gene of H9N2 influenza viruses isolated from Asia. Research in Veterinary Science. 2012; 93:234-9.
21. OIE Terrestrial Manual. Avian Influenza (Infections with avian influenza viruses). Chapter 2.3.4. 2005.
22. National Research Council. Guide for the Care and Use of Laboratory Animals. 8 th ed. National Academies Press. Washington DC. 2010.
23. Singh H. Vaccines adjuvants and delivery systems: mechanism of adjuvants action, Novartis Vaccines, Wiley-Interscience Publication, California. 2007.
24. Wang W, Li Q, Zhang J, Wu H, Yin Y, Ge Q, et al. Hemokinin-1 activates the MAPK pathway and enhances B cell proliferation and antibody production. The Journal of Immunology. 2010; 184:3590-7.
25. Grassin-Delyle S, Buenestado A, Vallat L, Naline E, Marx S, Decocq J, et al. Expression and proliferative effect of hemokinin-1 in human B-cells. Peptides. 2011; 32:1027-34.
26. Des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. Journal Control Release. 2006; 116: 1-27.
27. Riteau N, She A. Chitosan: An adjuvant with an unanticipated STING. Immunity. 2016; 44: 522-4.
28. Borges O, Borchard G, de Sousa A, Junginger HE, Cordeiro-da-Silva A. Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. International Journal of Pharmacology. 2007; 337:254-264.
29. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, et al. Recent advances of chitosan nanoparticles as drug carriers. International Journal of Nanomedicine. 2011; 6: 765-74.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
